A study of axelopran with immunotherapy for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests if adding a drug called axelopran (which blocks opioid effects that may weaken the immune system) to the standard immunotherapy pembrolizumab can help treat head and neck cancer that has come back or spread. You may qualify if you have this type of cancer, are planning to start or are already on opioid pain medication, and your tumor tests positive for a protein called PD-L1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You have head and neck cancer (specifically squamous cell carcinoma) that has returned or spread and cannot be cured by local treatments
- You are planning to receive pembrolizumab as your first treatment for this cancer, or you had platinum chemotherapy before and it stopped working within 3 to 6 months
- Your tumor has a PD-L1 score greater than 1 (a test your doctor can do)
- You are taking or will start taking opioid pain medication for cancer pain
- You have adequate organ function (checked by blood tests) and are able to perform daily activities with little to no help
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Hear when a new Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.